GMA is the global / international marketing agency treating this city as a buyer-evaluation problem inside market-entry marketing. The work is the local-market website, proof order, offer language, SEO/AI visibility, paid path, and follow-up a foreign or outbound company needs before serious buyers move.
Two hundred CEE sites. Thousands of patients. Strong outcomes data. The US value-analysis committee files the device as untested. CEE deployment depth is invisible to US procurement scoring. The procurement scoring judges a different evidence stack.
If two hundred CEE sites does not register and one US pilot site does, the US procurement evaluation function is the issue, not the product.
CEE medtech evaluation is structured around clinical literature, CE-mark history, named-site adoption across CEE health systems, and national-payer reimbursement decisions. A device with deep CEE penetration lands as field-proven and well-supported. Procurement and clinical evaluation are tightly coupled in the CEE health systems. The Austrian medtech firm with broad CEE deployment carries strong evidence at home and across the region.
US IDN procurement evaluation is structured around the procurement function rather than the clinical function. The value-analysis committee scores on six US-market signals: FDA pathway and clearance status, GPO contract availability, CMS coding and reimbursement clarity, US clinical evidence with US sites and US authors, US KOL adoption, and total cost of care impact in US accounting language. CEE clinical literature, while substantive, is not weighted against any of these six. The Austrian file led by CEE depth without the US-market signals is filed under untested.
Per Roland Berger medtech outlook and IMAP life sciences M&A report, US IDN procurement scoring weights US-site clinical data and US-coded cost-of-care framing over equivalent CEE or European data. Reuters US hospital procurement coverage 2024-2026 documents the tightening of total cost of care framing across major US IDNs.
The fix is the same as for other European medtech files, with a specific note on CEE. CEE deployment data must be restated in US-market form, with TCO modelling and US accounting language. Where US clinical sites do not yet exist, one US site has to be stood up. The US channel structure has to be built: GPO contract relationship, CMS coding documentation, FDA status restated, US KOL strategy. 6 signals, placed where US procurement judges them.
If you placed your CEE deployment number next to a US-domestic medtech's single US clinical site report tomorrow, which one does the US procurement officer score higher?
"Two hundred CEE sites is real. The US procurement officer scores one US site higher. Build the US site."House view on Austrian medtech US entry
Stage one: evaluate the file against the six signals. Score the US-facing materials against FDA pathway and status, GPO contract availability, CMS coding and reimbursement clarity, US clinical evidence with US sites and US authors, US KOL adoption, and total cost of care impact in US accounting language. Name every signal that is absent. CEE deployment numbers are kept as support, not as lead.
Stage two: rebuild the file and anchor one US site. Restructure the US website, deck, and sales material and the value-analysis dossier to lead with the six signals. Anchor one US clinical site with named US investigators producing US-published outcome data, even in modest patient numbers. Build a TCO model in US accounting language that translates the CEE outcome data into IDN-relevant savings.
Stage three: brief the US channel and the value-analysis committee. The US sales team is briefed on how to present the six signals in the VAC meeting. The IDN value-analysis committee is approached with a dossier structured around their evaluation order. The GPO outreach is restarted with a contract-fit package. The CEE deployment data is presented as supportive geographic depth rather than as the lead claim.
This work fits inside a Market-Entry Marketing Sprint (six to ten weeks, one IDN segment, one device line), a Cross-Border Marketing Build (three to six months, full US procurement and channel rebuild), or a Global Marketing Partnership (monthly retainer, twelve-month minimum, for groups with multiple US-facing medtech lines). Pricing is discussed privately after GMA knows the work needed.
| Before rebuild (CEE register) | After rebuild (US procurement register) |
|---|---|
| Lead signal: CEE deployment count and CE-mark | Lead signal: FDA status, GPO contract, CMS coding visible |
| Clinical evidence: CEE sites and CEE authors | Clinical evidence: one named US site, US authors, US-published |
| Cost narrative: device price comparison | Cost narrative: TCO model in US accounting language |
| KOL strategy: CEE-led | KOL strategy: US-named, US-society-aligned |
| Pilot expansion: zero | Pilot expansion: IDN-wide on the strength of the rebuilt file |
| VAC outcome: filed untested | VAC outcome: scored in the evaluation set, contract path open |
File first, US site second, channel third. CEE deployment is the support. The US site is the lead.
US integrated delivery network procurement judges a specific evidence stack: FDA pathway and clearance status, GPO contract availability, CMS coding and reimbursement, US clinical evidence with US sites and US authors, US KOL adoption, and total cost of care impact in US accounting language. CEE deployment data lands as supportive geographic experience but does not substitute for any of the six US-market signals. A Vienna medtech with 200 CEE sites and zero US-market evidence lands as untested in the US procurement scoring.
Six things: FDA status with the specific clearance pathway, GPO contract availability, CMS coding and reimbursement clarity, US clinical evidence with US sites and US authors, US KOL adoption, and total cost of care impact in US accounting language. CEE clinical literature and CE-mark land as supportive only. The Austrian medtech file led by CEE deployment depth without these six is filed under untested.
Not useless. Useful in support, not as the lead. CEE deployment numbers tell the US procurement buyer that the device is field-proven in volume. That is helpful background. It does not score the procurement. The fix is to restate CEE data in the US format with TCO modelling, while building the US clinical site presence and the GPO contract conversation in parallel.
Less than firms expect, more than firms typically provide. One named US clinical site with US investigators producing US-published outcome data, even in modest patient numbers, moves the file out of untested. Combined with a TCO model in US accounting language and a structured GPO outreach, the device is back in the evaluation set within one VAC cycle. Per Roland Berger medtech outlook, US procurement buyers explicitly weight one US clinical site above significant European or CEE site numbers for first-evaluate scoring.
Inquiry through the contact form and a first fit screening. Share the current US-facing materials, the FDA status and pathway document, the CEE deployment and clinical pack, the last three IDN evaluations, and the GPO outreach record. Response within one business day. Pricing is discussed privately after GMA knows the work needed.
No legal services. No FDA submissions, no 510(k), De Novo, or PMA filings. No CE-mark or notified-body work. No clinical trial design, IRB submissions, or regulatory medical writing. No GPO contract negotiation. No CMS coding or reimbursement filings. No HIPAA, SaMD, or device cybersecurity certification. No US, Austrian, or other-jurisdiction entity formation. No US tax structuring. No US banking introductions. No fiduciary services. No IP filing. No M&A transaction work. The clinical and regulatory substance sits with regulatory counsel, clinical research organisations, and reimbursement consultants on both sides of the corridor. GMA rebuilds the commercial and procurement-facing surface that runs alongside the regulatory and clinical file. When a marketing decision touches clinical, regulatory, or reimbursement implications, GMA flags it and defers before execution.
If the market is not responding, the first question is simple: what is the buyer not seeing, trusting, or doing yet?
| Action that should happen | The buyer should request a quote, ask for a call, send an RFQ, move a proposal forward, or hand the work to the right internal person. |
| What may be unclear | If that is not happening, the market may not understand the category, proof, offer, price, channel, service answer, or follow-up. |
| What to inspect | Check the page, sales deck, product proof, offer language, contact path, and follow-up before adding more traffic or more distributors. |
| Next step | If the break is commercial, continue to /engagements/ or /contact/#inquiry. |